tetrahydrozoline (CID 5419) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(2)
 
 
Inactive(64)
 
 
Inconclusive(2)
 
 
Unspecified(20)
 
 
Top Targets:
7TM GPCR Srx(4)
 
 
 
PIKKc TOR(4)
 
 
Pyr redox dim(4)
 
 
BRLZ(2)
 
 
PIN FEN1(2)
 
 
BioAssay Types:
Confirmatory(53)
 
 
 
Literature(25)
 
 
 
 
Screening(10)
 
 
BioActivity Types:
Potency(53)
 
 
 
IC50(2)
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 87    Data Row: 88   Total Pages: 2   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103391481]
IC50 0.03Binding affinity against Alpha-2 adrenergic receptor is the ability to inhibit the specific [3H]clonidine binding (0.4 nM) to rat isolated brain membranes by 50% was reported; 3.0*10e-8 [AID36790, Type: Literature]
View
2
[SID103391481]
IC50 1.6Binding affinity against alpha-1 adrenergic receptor is the ability to inhibit the specific [3H]prazosin binding (0.2 nM) to rat isolated brain membranes by 50% was reported; 1.6*10e-6 [AID36717, Type: Literature]
View
3
[SID103391481]
 Apparent partion coefficient of compound was evaluated in octanol/buffer at pH of 7.4 at 37 degree Centigrade [AID23715, Type: Literature]
View
4
[SID103391481]
 Hypotensive activity (25% decrease in arterial pressure) after i.v. administration to anesthetized normotensive rats. [AID197167, Type: Literature]
View
5
[SID103391481]
 Hypertensive activity (increase in arterial pressure to 60 mmHg)) after i.v. administration to pithed rats. [AID197169, Type: Literature]
View
6
[SID103391481]
 Partition coefficient (logD7.4) [AID23716, Type: Literature]
View
7
[SID103391481]
 Central hypotensive activity in anesthetized normotensive rats. [AID33250, Type: Literature]
View
8
[SID103391481]
 Peripheral hypertensive activity in pithed normotensive rats. [AID33252, Type: Literature]
View
9
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia [AID625279, Type: Literature]
View
10
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis [AID625282, Type: Literature]
View
11
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests [AID625283, Type: Literature]
View
12
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure [AID625284, Type: Literature]
View
13
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis [AID625285, Type: Literature]
View
14
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis [AID625286, Type: Literature]
View
15
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly [AID625287, Type: Literature]
View
16
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice [AID625288, Type: Literature]
View
17
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease [AID625289, Type: Literature]
View
18
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty [AID625290, Type: Literature]
View
19
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal [AID625291, Type: Literature]
View
20
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score [AID625292, Type: Literature]
View
21
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis [AID625280, Type: Literature]
View
22
[SID103391481]
 Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis [AID625281, Type: Literature]
View
23
[SID90341828]
Potency 0.0299Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS [AID504845, Type: confirmatory]regulator of G-protein signaling 4 [Homo sapiens] [gi:86301163]
View
24
[SID90341828]
Potency 0.0299Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS [AID504845, Type: confirmatory]regulator of G-protein signaling 4 [Homo sapiens] [gi:86301163]
View
25
[SID90341828]
Potency 0.0299Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS [AID504845, Type: confirmatory]regulator of G-protein signaling 4 [Homo sapiens] [gi:86301163]
View
26
[SID90341828]
Potency 14.1254qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS [AID588453, Type: confirmatory]thioredoxin reductase [Rattus norvegicus] [gi:8659577]
View
27
[SID90341828]
Potency 14.1254qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS [AID588453, Type: confirmatory]thioredoxin reductase [Rattus norvegicus] [gi:8659577]
View
28
[SID90341828]
Potency 31.6228qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation [AID624146, Type: confirmatory]GLS protein [Homo sapiens] [gi:71051501]
View
29
[SID85788488]
 Development of IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity [AID624101, Type: screening]Isocitrate dehydrogenase 1 (NADP+), soluble [Homo sapiens] [gi:62203298]
View
30
[SID85788488]
 Development of IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity [AID624101, Type: screening]Isocitrate dehydrogenase 1 (NADP+), soluble [Homo sapiens] [gi:62203298]
View
31
[SID85788488]
 Development of IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity [AID624101, Type: screening]Isocitrate dehydrogenase 1 (NADP+), soluble [Homo sapiens] [gi:62203298]
View
32
[SID85788488]
 Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF [AID2240, Type: screening]microphthalmia-associated transcription factor isoform 1 [Homo sapiens] [gi:38156699]
View
33
[SID85788488]
 Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF [AID2240, Type: screening]microphthalmia-associated transcription factor isoform 1 [Homo sapiens] [gi:38156699]
View
34
[SID90341828]
Potency qHTS of Nrf2 Activators: LOPAC Validation [AID624149, Type: confirmatory]Nrf2 [Homo sapiens] [gi:693842]
View
35
[SID90341828]
Potency qHTS of Nrf2 Activators: LOPAC Validation [AID624149, Type: confirmatory]Nrf2 [Homo sapiens] [gi:693842]
View
36
[SID90341828]
Potency qHTS of Nrf2 Activators: LOPAC Validation [AID624149, Type: confirmatory]Nrf2 [Homo sapiens] [gi:693842]
View
37
[SID90341828]
Potency qHTS of Nrf2 Activators: LOPAC Validation [AID624149, Type: confirmatory]Nrf2 [Homo sapiens] [gi:693842]
View
38
[SID90341828]
Potency Nrf2 qHTS screen for inhibitors: Validation [AID493153, Type: confirmatory]nuclear factor erythroid 2-related factor 2 isoform 2 [Homo sapiens] [gi:224028257]
View
39
[SID90341828]
Potency Nrf2 qHTS screen for inhibitors: Validation [AID493153, Type: confirmatory]nuclear factor erythroid 2-related factor 2 isoform 2 [Homo sapiens] [gi:224028257]
View
40
[SID90341828]
Potency Nrf2 qHTS screen for inhibitors: Validation [AID493153, Type: confirmatory]nuclear factor erythroid 2-related factor 2 isoform 2 [Homo sapiens] [gi:224028257]
View
41
[SID90341828]
Potency Nrf2 qHTS screen for inhibitors: Validation [AID493153, Type: confirmatory]nuclear factor erythroid 2-related factor 2 isoform 2 [Homo sapiens] [gi:224028257]
View
42
[SID90341828]
Potency qHTS Assay for NPC1 Promoter Activators [AID485313, Type: confirmatory]NPC1 gene product [Homo sapiens] [gi:255652944]
View
43
[SID90341828]
Potency qHTS Validation Assay to Find Inhibitors of Pin1 [AID504536, Type: confirmatory]PIN1 gene product [Homo sapiens] [gi:5453898]
View
44
[SID90341828]
Potency qHTS Validation Assay to Find Inhibitors of Pin1 [AID504536, Type: confirmatory]PIN1 gene product [Homo sapiens] [gi:5453898]
View
45
[SID90341828]
Potency HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists [AID488983, Type: confirmatory]D(1A) dopamine receptor [Homo sapiens] [gi:4503383]
View
46
[SID90341828]
Potency HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists [AID488983, Type: confirmatory]D(1A) dopamine receptor [Homo sapiens] [gi:4503383]
View
47
[SID90341828]
Potency HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists [AID488983, Type: confirmatory]D(1A) dopamine receptor [Homo sapiens] [gi:4503383]
View
48
[SID90341828]
Potency HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists [AID488983, Type: confirmatory]D(1A) dopamine receptor [Homo sapiens] [gi:4503383]
View
49
[SID90341828]
Potency HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF [AID624455, Type: confirmatory]dopamine D1 receptor [Homo sapiens] [gi:299681]
View
50
[SID90341828]
Potency HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF [AID624455, Type: confirmatory]dopamine D1 receptor [Homo sapiens] [gi:299681]
View